Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
0 competitors in Kidney Transplantation in Highly Sensitized Patients
View Full LandscapeTarget Indication
Kidney Transplantation in Highly Sensitized Patients
Clinical Trial
NCT04935177Last updated: 6/28/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Idefirix
Idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. The use of Idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.